Scarica l'app Stockscreener
23.90
0.81%
-0.195
Precedente Chiudi:
$24.09
Aprire:
$24.27
Volume 24 ore:
262.39K
Relative Volume:
0.53
Capitalizzazione di mercato:
$1.06B
Reddito:
-
Utile/perdita netta:
$-166.31M
Rapporto P/E:
-5.3585
EPS:
-4.4602
Flusso di cassa netto:
$-160.59M
1 W Prestazione:
+2.01%
1M Prestazione:
+6.41%
6M Prestazione:
+21.26%
1 anno Prestazione:
+9.89%
Intervallo 1D:
$23.70
$25.00
Intervallo di 1 settimana:
$23.04
$26.86
Portata 52W:
$15.47
$27.22
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Nome
Arrivent Biopharma Inc
Settore
Industria
Telefono
240-780-6356
Indirizzo
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
23.90 | 1.06B | 0 | -166.31M | -160.59M | -4.4602 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-12 | Ripresa | BTIG Research | Buy |
| 2025-12-10 | Iniziato | BTIG Research | Buy |
| 2025-11-25 | Iniziato | Truist | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-03-20 | Iniziato | B. Riley Securities | Buy |
| 2025-03-10 | Iniziato | Guggenheim | Buy |
| 2024-07-22 | Iniziato | Oppenheimer | Outperform |
| 2024-04-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-20 | Iniziato | Citigroup | Buy |
| 2024-02-20 | Iniziato | Goldman | Buy |
| 2024-02-20 | Iniziato | Jefferies | Buy |
Mostra tutto
Arrivent Biopharma Inc Borsa (AVBP) Ultime notizie
Behavioral Patterns of AVBP and Institutional Flows - Stock Traders Daily
ArriVent BioPharma's (AVBP) Buy Rating Reaffirmed at BTIG Research - MarketBeat
ArriVent: Undervalued EGFR Franchise With Pivotal Firmonertinib Upside and Emerging ADC Optionality Driving Buy Rating and $42 Target - TipRanks
BTIG initiates ArriVent stock coverage with buy rating on oncology pipeline - Investing.com Canada
ArriVent Reports 2025 Results, Plans Phase 3 Data for Firmonertinib - MyChesCo
ArriVent BioPharma (NASDAQ:AVBP) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Is ArriVent BioPharma, Inc. (AVBP) Shares Surpassing Other Medical Stocks in Performance This Year? - Bitget
Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High? - Yahoo Finance
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
A Look At ArriVent BioPharma (AVBP) Valuation After Recent Share Price Swings - Sahm
Whats the profit margin of ArriVent BioPharma IncWeekly Trend Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
ArriVent BioPharma's (AVBP) Outperform Rating Reaffirmed at Oppenheimer - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $33.00 - MarketBeat
Is ArriVent BioPharma (AVBP) Pricing Reflect Its DCF Value After Recent Share Gains - simplywall.st
ArriVent BioPharma Sees Unusually High Options Volume (NASDAQ:AVBP) - MarketBeat
Oppenheimer Adjusts Price Target on ArriVent BioPharma to $50 From $44, Maintains Outperform Rating - marketscreener.com
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $44.00 - MarketBeat
Jones Trading Initiates Coverage of ArriVent BioPharma (AVBP) with Buy Recommendation - MSN
ArriVent BioPharma Reports 2025 Financial Results and Advances Firmonertinib & ADC Pipeline with Key Phase 3 NSCLC Trials and Cash Runway Into 2027 - Minichart
EPS Watch: Whats next for ArriVent BioPharma Inc stock2025 Buyback Activity & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
ArriVent BioPharma (NASDAQ:AVBP) Announces Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
ArriVent BioPharma Reports Full Year 2025 Financial Results - Bitget
ArriVent lines up mid-2026 lung cancer data, backed by $312.8M cash - Stock Titan
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
AVBP PE Ratio & Valuation, Is AVBP Overvalued - Intellectia AI
ArriVent BioPharma (NASDAQ:AVBP) Hits New 12-Month HighHere's What Happened - MarketBeat
(AVBP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
AVBP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
ArriVent BioPharma, Inc. (AVBP): Investor Outlook With A Promising 73% Potential Upside - DirectorsTalk Interviews
ArriVent BioPharma (AVBP) Stock Analysis Report | Financials & Insights - Benzinga
Risk Analysis: Whats next for ArriVent BioPharma Inc stockGap Down & AI Forecasted Entry/Exit Points - baoquankhu1.vn
ArriVent BioPharma (AVBP) Projected to Post Earnings on Monday - MarketBeat
AVBPArrivent Biopharma Inc Latest Stock News & Market Updates - Stock Titan
How much upside does ArriVent BioPharma Inc. haveWeekly Loss Report & Consistent Growth Stock Picks - mfd.ru
Can ArriVent BioPharma Inc. keep up with sector leadersQuarterly Market Review & High Accuracy Trade Alerts - mfd.ru
Is ArriVent BioPharma Inc. showing insider buyingJuly 2025 Sector Moves & Capital Efficiency Focused Strategies - mfd.ru
How (AVBP) Movements Inform Risk Allocation Models - Stock Traders Daily
Energy Transfer (ET) Among Top Holdings for Omega Advisors - GuruFocus
Insider Buy: How sensitive is ArriVent BioPharma Inc to inflationJuly 2025 Setups & Accurate Technical Buy Alerts - baoquankhu1.vn
Why ArriVent BioPharma Inc. stock remains resilientDay Trade & Smart Investment Allocation Insights - mfd.ru
Does ArriVent BioPharma Inc. have a sustainable dividend2025 Biggest Moves & Long-Term Safe Investment Ideas - mfd.ru
ArriVent BioPharma, Inc. (AVBP) Stock Analysis: Exploring a Potential 79.45% Upside for Biotech Enthusiasts - DirectorsTalk Interviews
ArriVent BioPharma (NASDAQ:AVBP) Trading Up 6.8%Still a Buy? - MarketBeat
Growth Prospects for the EGFR-NSCLC Market Analyzed - Intellectia AI
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 5.6%Here's Why - MarketBeat
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Trading Systems Reacting to (AVBP) Volatility - Stock Traders Daily
$207B Market Shift: The Race for Fast Track Approval in Oncology - The Malaysian Reserve
$207B Market Shift: The Race for Fast Track Approval in Oncology (2026-02-05) - Seeking Alpha
Aug Catalysts: Is ASTC a play on infrastructure spending2025 Performance Recap & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Arrivent Biopharma Inc Azioni (AVBP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):